AbbVie (NYSE:ABBV) Shares Down 1.5% Following Insider Selling

AbbVie Inc. (NYSE:ABBV)’s share price was down 1.5% on Thursday following insider selling activity. The company traded as low as $260.48 and last traded at $261.88. Approximately 5,125,653 shares changed hands during trading, a decline of 25% from the average daily volume of 6,870,330 shares. The stock had previously closed at $265.97.

Specifically, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research reports. Barclays boosted their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Piper Sandler lifted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday. Canaccord Genuity Group upped their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Guggenheim raised their price target on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.

AbbVie Stock Down 1.5%

The firm’s fifty day moving average price is $246.98 and its 200-day moving average price is $226.95. The stock has a market cap of $462.69 billion, a P/E ratio of 73.98, a PEG ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Advocacy Wealth Management LLC lifted its holdings in shares of AbbVie by 3.9% during the second quarter. Advocacy Wealth Management LLC now owns 3,814 shares of the company’s stock valued at $960,000 after purchasing an additional 143 shares during the last quarter. CTC Alternative Strategies Ltd. purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $2,869,000. M Holdings Securities Inc. grew its stake in shares of AbbVie by 3.9% in the 2nd quarter. M Holdings Securities Inc. now owns 23,422 shares of the company’s stock worth $5,664,000 after buying an additional 887 shares during the last quarter. Oarsman Capital Inc. increased its position in AbbVie by 3.4% during the 2nd quarter. Oarsman Capital Inc. now owns 20,266 shares of the company’s stock valued at $5,100,000 after buying an additional 668 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in AbbVie during the 2nd quarter valued at approximately $3,478,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.